An observational study in Obesity, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Vanderbilt University Medical Center · Observational
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Obesity by Vanderbilt University Medical Center — 7 open to participants now, 12 under way, 1 of them phase 3. Obesity · Vanderbilt University Medical Center.
Among the 40 studies in Obesity by Vanderbilt University Medical Center, this one is the only one that started in 2025, is one of 7 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 37th registered.
11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →7 of the 40 studies in Obesity by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 25–55
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18–65
Vanderbilt University Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 1 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 29 across the 33 interventional studies, 75 across the 7 observational. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
5 of the studies in Obesity by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03318094Vanderbilt University Medical CenterRole of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity | 2026-11-30 |
| NCT04971044Vanderbilt University Medical CenterCompetency Based Approaches for Community Health 2 | 2026-12 |
| NCT07115069Vanderbilt University Medical CenterComparison of Body Composition Changes With Weight Loss Interventions | 2027-06 |
| NCT05972564Vanderbilt University Medical CenterThe Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function | 2027-06-30 |
| NCT07011628Vanderbilt University Medical CenterTransition to Ambulatory Bariatric Surgery (TABS) Trial | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Obesity by Vanderbilt University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways.
The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels.
The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.
Patients are benefiting from landmark advancements in obesity treatments with the advent of Glucagon-like Peptide 1 Receptor agonists (GLP1RA) such as semaglutide and tirzepatide, which achieve weight loss of 15-20% in clinical trials.2,4,21 However, numerous questions surround the safety and efficacy of GLP1RAs compared to established surgical interventions. Minimally Invasive gastric bypass (GB) remains the benchmark for obesity treatments, with superior weight loss of 25-35%, and an extensive body of literature demonstrating long-term safety and efficacy, with rare complications and dramatic improvements in obesity-related comorbidities and quality of life.22,23 To date, an absence of guidelines exists to guide patients and clinicians in appropriate selection of therapies for obesity, largely resulting from the lack of head-to-head comparison for safety and efficacy of these interventions.
GLP1RAs carry several risks potentially limiting their benefit. The appetite suppression induced by GLP1RAs may result in disproportionate skeletal muscle depletion, the magnitude of which remains incompletely characterized.24,25 Loss of skeletal muscle can lead to poorer functional outcomes despite weight loss, and may lead to sarcopenic obesity if weight regain occurs after drug cessation.7,10 Additionally, a majority of patients taking GLP1RAs report adverse gastrointestinal (GI) symptoms including nausea, vomiting, constipation and abdominal pain, with reported discontinuation rates of >50% in clinical practice.26-29 Furthermore, the significant cost of GLP1RAs (averaging $10,000-15,000 annually) has placed considerable strain on healthcare systems. Recent studies suggest long-term cost benefits of GB over GLP1RAs30, but more research is needed to further delineate the most effective strategy in terms of both clinical outcomes and economic impact.
This study aims to compare impact of GLP1RAs and GB on skeletal muscle composition, GI symptom profiles, and quality of life metrics. This study will also compare changes in GI symptoms and quality of life between patients undergoing laparoscopic versus robotic GB.
Specific Aim 1: Compare change in appendicular lean body mass (LBM) after GLP-1 receptor agonists \& gastric bypass at 3, 6, and 12 months. Utilizing Dual-Energy X-ray Absorptiometry (DXA) scans conducted prior to surgery or mediation initiation and 3-, 6-, and 12-months post-intervention, the investigators will quantify the ratio of LBM loss to total weight loss with GLP1RAs and GB surgery. The investigators hypothesize that GLP1RA treatment will result in greater proportional loss of LBM than GB after 12 months of treatment. Data will be analyzed using mixed-effects models accounting for baseline characteristics and intervention type.
Specific Aim 2: Compare GI symptoms changes and overall quality of life following gastric bypass vs GLP1RAs and investigate real-world tolerability of GLP1RAs. Utilizing the validated Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM), administered at baseline and monthly intervals for 6 months, this study will compare the trajectory and severity of GI symptoms between those receiving GLP1RA and those who undergo GB. The investigators hypothesize that GLP1RA treatment will result in higher (worse) PAGI-SYM scores than GB throughout the study period. Additionally, will measure Health Related Quality of Life (HRQOL) monthly from intervention to 6 months post-intervention and compare trajectory of overall HRQOL after GLP1RA and GB.
Specific Aim 3: Comparison of GI symptoms and quality of life changes at 3 and 6 mo with robotic surgery and GLP1RA therapies. The investigators will also study how robotic GB compares to GLP1RA therapy in terms of GI symptomatology and health-related quality of life (HRQOL). HRQOL will be assessed using the validated SF-36 and the obesity-specific IWQOL-Lite instruments at baseline, 3 months, 6 months, and 12 months.
Participants seeking medical or surgical weight loss for class III obesity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient recieving Glucagon Like Peptide 1 Receptor Agonists (GLP1RA) or incretin polyagonists.
Drug: GLP-1 receptor agonist
Patients undergoing gastric bypass laparoscopically
Procedure: Gastric Bypass Surgery (laparoscopic)
Patients undergoing Gastric Bypass surgery robotically
Procedure: Gastric Bypass Surgery (robotic)
Any FDA-approved GLP-1 receptor agonist
Also known as: semaglutide, tirzepatide
Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
Also known as: RNYGB
Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
Also known as: RNYGB
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Skeletal Muscle Loss
loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 6 months as determined by DXA
Time frame: 6 months
Skeletal Muscle Loss
loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 12 months as determined by DXA
Time frame: 12 months
Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire
Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.
Time frame: 6 months
Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire
Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.
Time frame: 12 months
Incidence of 10% weight loss
Number of patients achieving ≥10% total body weight loss
Time frame: 6 months
Incidence of 10% weight loss
Number of patients achieving ≥10% total body weight loss
Time frame: 12 months
Incidence of 15% weight loss
Number of patients achieving ≥15% total body weight loss
Time frame: 6 months
Incidence of 15% weight loss
Number of patients achieving ≥15% total body weight loss
Time frame: 12 months
Grip Strength
Change in Grip strength measured by Jamar Grip Strength Hydraulic Dynanometer.
Time frame: 3, 6, and 12 months
PAGI-SYM sub-scale scores
Sub-scale scores: 1. heartburn/regurgitation, 2. nausea/vomiting, 3. postprandial fullness, 4. bloating, 5. upper and lower abdominal pain
Time frame: 6 months
Plan to share: Yes — Any sharing of de-identified data for scientific dissemination (e.g., publications, presentations) will comply with federal guidance and institutional requirements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: At least 5 years after study end
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 22 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →